Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Gross Profit (2016 - 2025)

Haemonetics has reported Gross Profit over the past 17 years, most recently at $202.4 million for Q4 2025.

  • Quarterly results put Gross Profit at $202.4 million for Q4 2025, up 4.57% from a year ago — trailing twelve months through Dec 2025 was $782.4 million (up 6.92% YoY), and the annual figure for FY2025 was $749.0 million, up 8.3%.
  • Gross Profit for Q4 2025 was $202.4 million at Haemonetics, up from $194.7 million in the prior quarter.
  • Over the last five years, Gross Profit for HAE hit a ceiling of $202.4 million in Q4 2025 and a floor of $81.8 million in Q2 2021.
  • Median Gross Profit over the past 5 years was $168.9 million (2023), compared with a mean of $161.6 million.
  • Biggest five-year swings in Gross Profit: fell 27.96% in 2021 and later surged 66.63% in 2022.
  • Haemonetics' Gross Profit stood at $122.5 million in 2021, then grew by 29.51% to $158.7 million in 2022, then grew by 12.07% to $177.9 million in 2023, then grew by 8.82% to $193.5 million in 2024, then rose by 4.57% to $202.4 million in 2025.
  • The last three reported values for Gross Profit were $202.4 million (Q4 2025), $194.7 million (Q3 2025), and $192.2 million (Q2 2025) per Business Quant data.